Last reviewed · How we verify
NCT05738538
Expanded Access to Ziftomenib
trial testing ziftomenib in Acute Lymphoblastic Leukemia, With Appropriate Mutations. Available.
Quick facts
| Lead sponsor | Kura Oncology, Inc. |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- ziftomenib (ZIFTOMENIB) — full drug profile →
Conditions studied
- Acute Lymphoblastic Leukemia, With Appropriate Mutations — all drugs for Acute Lymphoblastic Leukemia, With Appropriate Mutations →
- Acute Myeloid Leukemia, With NPM1 Mutations — all drugs for Acute Myeloid Leukemia, With NPM1 Mutations →
Sponsor
Kura Oncology, Inc. — full company profile →
Who can join
18 and older, any sex, with Acute Lymphoblastic Leukemia, With Appropriate Mutations or Acute Myeloid Leukemia, With NPM1 Mutations. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL) with KMT2A rearrangements, or Acute Myeloid Leukemia (AML), with NPM1 mutations or KMT2A rearrangements. To request access, use Responsible Party contact information provided in this record. Expanded access for ziftomenib is only available in the United States.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions.
Dhiman S, Dhillon V, Balasubramanian SK. · · 2024 · cited 6× · PMID 39594699 · DOI 10.3390/cancers16223743 -
Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells.
Murphy LA, Winters AC. · · 2023 · cited 6× · PMID 38137469 · DOI 10.3390/biomedicines11123248 -
<i>NPM1</i>-Mutated AML: Deciphering the Molecular and Clinical Puzzle in the Era of Novel Treatment Strategies.
Diamantidis MD, Vlachou MS, Katsikavela A, Kalomoiri S, et al · · 2025 · PMID 40647396 · DOI 10.3390/cancers17132095
Verify or expand the search:
- PubMed search for NCT05738538
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Kura Oncology, Inc. trials
Trials by the same sponsor.
- NCT05693090 — Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer · Phase 1 · withdrawn
- NCT04997902 — Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M · Phase 1, PHASE2 · completed
- NCT04865159 — Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies · Phase 1 · terminated
- NCT04067336 — First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · recruiting
- NCT03719690 — Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05738538 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kura Oncology, Inc.
- Last refreshed: 4 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05738538.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing